Physician profile
Matthew A Whitcomb
NPI 1881141471
$1,420.40
in general payments reported to CMS, 2019-2025
12 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $139 · 2023: $544 · 2024: $448 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.47 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $319.63 | 2023-2024 | Orserdu |
| Sobi, INC | $185.14 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $157.71 | 2024-2025 | Calquence |
| Beigene USA, INC. | $146.63 | 2023 | Brukinsa |
| Adc Therapeutics America, INC. | $142.71 | 2023 | |
| Janssen Biotech, INC. | $141.49 | 2025 | Carvykti, Rybrevant, Talvey |
| Adaptive Biotechnologies Corporation | $115.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $72.85 | 2024-2025 | |
| Abbvie INC. | $68.44 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.84 | 2023 | Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $23.39 | 2022 | |
| Merck Sharp & Dohme LLC | $22.02 | 2024 | Dificid, Prevymis, Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Whitcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.